VerImmune

Executive Summary

VerImmune is a biotechnology company pioneering a novel class of cancer immunotherapies based on its Anti-Tumor Immune Redirection (AIR) platform. Unlike traditional immunotherapies that aim to activate the immune system de novo, AIR leverages the body's pre-existing, pathogen-specific immune memory—such as that generated by childhood vaccines—and redirects it to recognize and attack solid tumors. This approach has the potential to induce potent, durable antitumor responses while minimizing the risk of autoimmunity and other side effects commonly associated with checkpoint inhibitors or CAR-T therapies. Founded in 2019 and headquartered in Rockville, Maryland, VerImmune is advancing its platform toward clinical development, focusing on solid tumors that currently have limited treatment options. The company is currently in the preclinical stage, focusing on lead candidate optimization and IND-enabling studies. If successful, the AIR platform could represent a paradigm shift in oncology by harnessing the immune system's memory in a targeted, controlled manner, offering a potentially safer and more effective alternative for patients with hard-to-treat cancers. VerImmune's immediate priorities include completing IND-enabling studies and securing partnership or financing to support a first-in-human trial. While the technology is early-stage and risks remain regarding translation from preclinical models to humans, the novelty and mechanistic rationale of AIR provide a compelling investment thesis in the emerging field of immune redirection.

Upcoming Catalysts (preview)

• Q3 2026IND Filing for Lead Program55% success
• Q2 2026Publication of Preclinical Proof-of-Concept Data70% success
• Q4 2026Series A Financing Round50% success